Strong financial and accounting experience, as well as extensive experience in delivering strategic outcomes. Amy Byrick is responsible for business development, strategy and digital transformation. She joined Novozymes in April 2021 from DuPont Nutrition & Biosciences, where she led the global food and beverage business. Prior to DuPont, Amy spent more than a decade at Amcor, where she held various strategic, marketing and general management positions. Amy holds Canadian and French citizenship and lives in Denmark. She holds a Bachelor of Chemical Engineering from Queen`s University and an MBA from INSEAD. Vice-Chairman of the Board of Directors. Member of the Audit Committee and the Appointments and Remuneration Committee. Member of the Board of Directors since 2020. Elected for one year at a time.

Anders Lund (born 1973) is responsible for application research, technical service, sales and marketing in the Consumer Biosolutions division. Executive Vice President, Operations, Procurement and Quality. Morten Enggaard Rasmussen, CSO and Executive Vice President, Research and Development, is responsible for our employee agenda, sustainability leadership and brand. He joined Novozymes in April 2021 after serving as Vice President of Human Resources and Culture at Vestas, responsible for Asia Pacific and China, based in Singapore. He joined Vestas in 2008 and has a strong track record of building and developing high-performing teams in North America, Europe, Africa and Asia, with a particular focus on sustainable business. Morten has proven its ability to manage complex international development projects and has served as a trusted business partner in various roles and geographies. Morten is a Danish citizen and holds a Master of Science degree from the Aarhus School of Business. How would you rate your overall experience with this company? Extensive international business experience in sales and marketing, emerging markets, innovation pipeline management and sustainability. That member of the board of directors shall not be considered independent within the meaning of the Danish recommendations on corporate governance applicable to Danish listed companies.

Novozymes Inc 1445 Drew Avenue Davis, CA 95618 (530) 757-4715 When viewing an ad, consider the government advertising restrictions that lawyers and law firms must comply with, as well as our legal directory disclaimer Some lawyers publish comparative information about the services they offer, which may be subject to specific comparative disclosure restrictions. Please let us know how you feel working with this law firm. Do not disclose any personal information or details about your case. All opinions submitted will be shared with the law firm prior to publication. Use the up and down arrows to increase or decrease the assessment Extensive international experience in business research and innovation pipeline management. Expertise in international business and management, particularly in the areas of sales, marketing, branding, acquisitions, finance and accounting. Professor of Microbiology at the Technical University of Denmark (DTU). Member of the Innovation Committee. Elected for one year at a time. Executive Vice President, Strategy and Business Transformation Extensive experience in biotechnology, mergers and acquisitions, finance and accounting. It`s always a good idea to research your lawyer before hiring them.

Each state has a disciplinary organization that oversees attorneys, their licenses, and consumer complaints. By researching the legal discipline, you can: The ordinary shares consist of 282,000,000 shares, all with a par value of DKK 2 per share. The common shares are divided into 53,743,600 A shares with 20 votes each and 228,256,400 B shares with 2 votes each. Novozymes had more than 57,000 shareholders at the end of 2021 and approximately 74% of B shares were held outside Denmark, mainly by institutional investors. Fifty institutional investors, including Novo Holdings A/S, held approximately 62% of the shares of B. Novo Holdings A/S held 25.5% of the total common shares of Novozymes and controlled 72.6% of the voting rights. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation, an independent Danish foundation whose objective is to provide a stable base for the companies of the Novo Group and to support scientific and humanitarian objectives. Anders has a strong commercial and strategic background and has been instrumental in shaping Novozymes` strategies over the past 10 years. He also brings strong client relationships, particularly in the areas of home care and biofuels.

Anders has been with Novozymes since graduating from Aarhus University, Denmark, in 1999. Over the course of his career, he has held several leadership positions, responsible for household care marketing, supply chain management and global marketing. Most recently, he was Vice President of Commercial Operations, Americas. Member of the Innovation Committee. Workers` representatives. From 2013 to 2016, she was Vice President of Commercial Operations for Europe, Middle East and Africa. Tina has extensive experience in developing and managing global partnerships and has been instrumental in negotiating several key contracts for Novozymes over the years. Ester is an experienced international leader with a strong track record. Ester joined Novozymes after serving as President of Dow`s Industrial Solutions business and a member of the management team. She joined Dow in Tarragona, Spain, in 1995 as an engineer. During her years as Commercial President of Industrial Solutions, the company has expanded the market, improved its market leadership position, achieved double-digit growth and strong results.